Scarica l'app Stockscreener
10.50
0.57%
-0.06
Dopo l'orario di chiusura:
10.50
Precedente Chiudi:
$10.56
Aprire:
$10.61
Volume 24 ore:
288.17K
Relative Volume:
1.85
Capitalizzazione di mercato:
$2.40B
Reddito:
$391.87M
Utile/perdita netta:
$-441.45M
Rapporto P/E:
-5.6757
EPS:
-1.85
Flusso di cassa netto:
$-301.21M
1 W Prestazione:
+32.24%
1M Prestazione:
+23.09%
6M Prestazione:
-13.01%
1 anno Prestazione:
-21.35%
Intervallo 1D:
$10.42
$10.81
Intervallo di 1 settimana:
$9.0301
$10.81
Portata 52W:
$7.35
$14.65
Alvotech Stock (ALVO) Company Profile
Confronta ALVO con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ALVO
Alvotech
|
10.50 | 2.40B | 391.87M | -441.45M | -301.21M | -1.85 |
|
ZTS
Zoetis Inc
|
154.92 | 69.45B | 9.29B | 2.52B | 2.28B | 5.57 |
|
HLN
Haleon Plc Adr
|
10.40 | 48.49B | 14.35B | 1.85B | 0 | 0.4023 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.71 | 47.40B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.89 | 20.19B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
299.68 | 13.84B | 2.99B | 1.21B | 1.13B | 25.06 |
Alvotech Stock (ALVO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-14 | Iniziato | UBS | Buy |
| 2024-01-29 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2023-10-20 | Aggiornamento | Citigroup | Sell → Neutral |
| 2023-09-21 | Iniziato | Barclays | Equal Weight |
| 2022-09-07 | Iniziato | Morgan Stanley | Equal-Weight |
| 2022-09-06 | Downgrade | Citigroup | Buy → Sell |
| 2022-07-26 | Iniziato | Citigroup | Buy |
Mostra tutto
Alvotech Borsa (ALVO) Ultime notizie
Alvotech at BofA Securities Healthcare Conference: Strategic Biosimilar Focus By Investing.com - Investing.com India
Alvogen Lux Holdings Acquires 210,000 Shares in Alvotech at ISK 1,277.38 - Nasdaq
Transactions of Managers and Closely Associated Persons - marketscreener.com
Alvotech Raises 2025 Revenue Guidance Amid Strong Performance - TipRanks
Teva, Alvotech receive FDA nod for interchangeability of Selardsdi with Stelara - Drug Store News
Analyst Estimates: Here's What Brokers Think Of Alvotech (NASDAQ:ALVO) After Its First-Quarter Report - Yahoo Finance
Alvotech CEO Acquires Significant Shareholding, Strengthening Market Confidence - TipRanks
Is Alvotech (ALVO) The Best Stock That Will Bounce Back? - Insider Monkey
Alvotech Meets Investors and Participates in Fireside Chat At the BofA Securities Healthcare Conference 2025 in Las Vegas, Nevada - The Manila Times
Alvotech Reports Strong Q1 2025 Earnings Growth - TipRanks
Alvotech earnings beat by $0.32, revenue topped estimates - Investing.com Nigeria
Alvotech sees minimal impact on 2025 product revenues from tariffs - MSN
Transcript : Alvotech, Q1 2025 Earnings Call, May 08, 2025 - marketscreener.com
Groupon Posts Upbeat Earnings, Joins Axon Enterprise, Warner Bros. Discovery, MercadoLibre And Other Big Stocks Moving Higher On Thursday - Benzinga
Alvotech Announces Webcast of First Quarter 2025 Financial Results on May 8, 2025, at 8:00 am EDT - marketscreener.com
Alvotech Reports Robust Q1 2025 Growth and Strategic Expansions - TipRanks
ACM Research Reports First Quarter 2025 Results - Stock Titan
Alvotech Publishes Prospectus in Connection with its Listing on Nasdaq Stockholm - The Manila Times
Alvotech Q1 2025 Earnings Call Transcript - MarketBeat
Alvotech (NASDAQ:ALVO) Sees Significant Growth in Short Interest - MarketBeat
Alvotech shares surge 6.6% as Q1 results top estimates By Investing.com - Investing.com Nigeria
Alvotech shares surge 6.6% as Q1 results top estimates - Investing.com
Alvotech Reports Results for the First Quarter of 2025 and Provides Business Update - The Manila Times
Alvotech Anticipates Minimal Impact from Potential U.S. Tariffs on Imported Pharmaceuticals in 2025 - Nasdaq
Alvotech Sees Minimal Impact On 2025 Revenues From U.S. Tariffs - marketscreener.com
Alvotech : Potential U.S. Tariffs on Pharmaceuticals Expected to Have Minimal Impact on Alvotech's Product Revenues in 2025 - marketscreener.com
Potential U.S. Tariffs on Pharmaceuticals Expected to Have Minimal Impact on Alvotech's Product Revenues in 2025 - The Manila Times
Potential U.S. Tariffs on Pharmaceuticals Expected to Have Minimal Impact on Alvotech’s Product Revenues in 2025 - Yahoo Home
Teva, Alvotech get FDA nod for Johnson & Johnson biosimilar - MSN
Teva And Alvotech Celebrate Interchangeability For US Ustekinumab - insights.citeline.com
FDA approves Teva-Alvotech biosimilar Selarsdi for multiple conditions - World Pharmaceutical Frontiers
Alvotech SA expected to post a loss of 11 cents a shareEarnings Preview - TradingView
FDA Approves SELARSDI from Alvotech (ALVO) as Interchangeable Bi - GuruFocus
Why Is Israel-Based Generic Drug Focused Teva Pharmaceutical Stock Trading Higher On Monday? - Benzinga
Teva, Alvotech announce FDA approval of interchangeability for SELARSDI - TipRanks
US FDA Approves Alvotech's Selarsdi for Full Interchangeability with J&J's Stelara - marketscreener.com
Teva and Alvotech stocks jump on FDA approval of SELARSDI By Investing.com - Investing.com Nigeria
Teva and Alvotech stocks jump on FDA approval of SELARSDI - Investing.com Australia
Teva, Alvotech: FDA approves interchangeability for SELARSDI with Stelara - TipRanks
Alvotech’s SELARSDI Gains FDA Approval for Interchangeability with Stelara - TipRanks
Teva and Alvotech Announce FDA Approval of Interchangeability for SELARSDI™ (ustekinumab-aekn) with Stelara® (ustekinumab) | TEVA Stock News - GuruFocus
Teva, Alvotech Get FDA Approval for Selarsdi's Interchangeablity With Stelara - marketscreener.com
Teva and Alvotech Announce FDA Approval of - GlobeNewswire
Teva and Alvotech Announce FDA Approval of Interchangeability for SELARSDI™ (ustekinumab-aekn) with Stelara® (ustekinumab) - finanzen.ch
FDA Grants Full Interchangeability to New Stelara Biosimilar for Multiple Autoimmune Conditions - Stock Titan
FDA Approval Boosts Alvotech's (ALVO) SELARSDI as Interchangeabl - GuruFocus
Alvotech to Announce Q1 2025 Financial Results on May 7, 2025, with Conference Call on May 8, 2025 - Nasdaq
Alvotech Announces Webcast of First Quarter 2025 Financial Results on May 8, 2025, at 8:00 am EDT (14:00 CET) - The Manila Times
Alvotech Announces Webcast of First Quarter 2025 Financial Results on May 8, 2025, at 8:00 am EDT (14 - marketscreener.com
REG-Alvotech Announces Webcast of First Quarter 2025 Financial Results on May 8, 2025, at 8:00 am EDT (14:00 CET) - TradingView
Alvotech Azioni (ALVO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.18%
0.28%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):